Details of the Drug Combination

General Information of Drug Combination (ID: DCWVH9V)

Drug Combination Name
Paromomycin Eptifibatide
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Paromomycin   DM1AGXN Eptifibatide   DMQXTJS
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 22.36
Bliss Independence Score: 22.36
Loewe Additivity Score: 37.33
LHighest Single Agent (HSA) Score: 37.34

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Paromomycin
Disease Entry ICD 11 Status REF
Amoebiasis 1A36 Approved [2]
Hepatic coma N.A. Approved [2]
Intestinal amebiasis 1A36 Approved [3]
Paromomycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) TTQ8KVI F4NA87_STAAU Binder [6]
------------------------------------------------------------------------------------
Paromomycin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Expression [7]
------------------------------------------------------------------------------------
Indication(s) of Eptifibatide
Disease Entry ICD 11 Status REF
Acute cardiac ischemic events BA40.Z Approved [4]
Acute coronary syndrome BA41 Approved [5]
Pneumonia CA40 Approved [5]
Eptifibatide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) TT38RM1 ITA2B_HUMAN; ITB3_HUMAN Modulator [8]
------------------------------------------------------------------------------------
Eptifibatide Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Prothrombin (F2) OTNFSM49 THRB_HUMAN Increases Expression [9]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Increases Expression [9]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [9]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [9]
Integrin alpha-IIb (ITGA2B) OT4Y17PY ITA2B_HUMAN Increases ADR [10]
Integrin beta-3 (ITGB3) OTWCK1K6 ITB3_HUMAN Increases ADR [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Paromomycin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064171.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6585).
5 Eptifibatide FDA Label
6 Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
7 Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15676-81. doi: 10.1073/pnas.0405155101. Epub 2004 Oct 21.
8 Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62.
9 Eptifibatide in peripheral vascular interventions: results of the Integrilin Reduces Inflammation in Peripheral Vascular Interventions (INFLAME) trial. J Invasive Cardiol. 2006 Jan;18(1):6-12.
10 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.